文献速递类风湿关节炎脊柱关节炎其他结缔组织病

生物制剂治疗严重难治性周边溃疡性角膜炎:34例多中心研究

Biologic therapy in severe and refractory peripheral ulcerative keratitis (PUK). Multicenter study of 34 patients.
PubMed 文献 · Semin Arthritis Rheum · 2020-05-15

该开放标签多中心研究评估了生物制剂治疗34例(44眼)对传统免疫抑制剂难治的严重周边溃疡性角膜炎(PUK)患者的疗效与安全性。主要结局指标在平均23.7±20个月随访中显示快速且持续改善,非抗TNFα药物组无需换药,但抗TNFα组48%需换用第二种生物制剂。

要点

  • 生物制剂对严重难治性PUK有效且相对安全。
  • 非抗TNFα药物在该人群中显示有效。
  • 抗TNFα药物治疗的患者中48%需换用第二种生物制剂。

核心结论

  • 生物制剂对严重且难治性PUK患者有效且相对安全。
  • 非抗TNFα药物似乎对这些患者有效。

研究设计与样本

  • 开放标签多中心研究,纳入34例(44只患眼)对传统免疫抑制剂难治的严重PUK患者,接受生物制剂治疗。

主要发现

  • 主要结局变量在平均23.7±20个月随访后显示快速且持续改善。
  • 25例使用抗TNFα药物的患者中12例(48%)需换用第二种生物制剂,而非抗TNFα药物组无需换药。
  • 主要不良事件包括快速耐受、反复呼吸道感染、室上性心动过速、肺结核和死亡各1例。

关键数值与推荐

  • 疗效通过角膜炎症(角膜变薄、中央角膜溶解和眼球穿孔)、其他眼表炎症(巩膜炎、表层巩膜炎)、眼内炎症(葡萄膜炎)、视力和糖皮质激素节约效应评估。

临床怎么用

  • 对于传统免疫抑制剂难治的严重PUK,可考虑使用生物制剂治疗。
  • 非抗TNFα药物可作为抗TNFα药物治疗失败或不耐受时的选择。

局限性

  • 开放标签设计可能引入偏倚。
  • 样本量较小(34例)。
  • 缺乏对照组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We assessed the efficacy and safety of biologic therapy in severe and refractory Peripheral Ulcerative Keratitis (PUK). DESIGN: Open-label multicenter study of biologic-treated patients with severe PUK refractory to conventional immunosuppressive drugs. SUBJECTS: We studied 34 patients (44 affected eyes) (24 women/10 men; mean age, 55.26±17.4 years). PUK was associated with a well-defined condition in 29 of them (rheumatoid arthritis [n = 20], psoriatic arthritis [n = 2], inflammatory bowel disease [n = 2], Behçet disease [n = 1], granulomatosis with polyangiitis [n = 1], microscopic polyangiitis [n = 1], systemic lupus erythematosus [n = 1] and axial spondyloarthritis [n = 1]). Besides topical and oral systemic glucocorticoids, patients had received: methylprednisolone pulses [n = 9], and conventional immunosuppressive drugs, mainly methotrexate [n = 18], and leflunomide [n = 7]. Eleven patients had required ocular surgery prior to biologic therapy. METHODS: Following biologic therapy, baseline main outcomes were compared with those found at 1st week, 1st and 6th months and 1st year. MAIN OUTCOME MEASURES: Efficacy and safety of biologic therapy. Efficacy was analyzed by the assessment of corneal inflammation (corneal thinning, central keratolysis and ocular perforation); other causes of ocular surface inflammation (scleritis, episcleritis); intraocular inflammation (uveitis); visual acuity and glucocorticoid sparing effect. RESULTS: The first biologic agents used were anti-TNFα drugs (n = 25); adalimumab (n = 16), infliximab (n = 8), etanercept (n = 1), and non-TNFα agents (n = 9); rituximab (n = 7), tocilizumab (n = 1) belimumab (n = 1) and abatacept (n = 1). During the follow-up, switching to a second biologic agent was required in 12 of the 25 (48%) patients treated with anti-TNFα drugs. However, no switching was required in those undergoing biologic therapy different from anti-TNFα agents. The main outcome variables showed a rapid and maintained improvement after a mean follow-up of 23.7 ± 20 months. Major adverse effects were tachyphylaxis, relapsing respiratory infections, supraventricular tachycardia, pulmonary tuberculosis and death, one each. CONCLUSIONS: Biologic therapy is effective and relatively safe in patients with severe and refractory PUK. Non-anti-TNFα agents appear to be effective in these patients.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Dominguez-Casas LC, Sánchez-Bilbao L, Calvo-Río V, et al. Biologic therapy in severe and refractory peripheral ulcerative keratitis (PUK). Multicenter study of 34 patients. Semin Arthritis Rheum. 2020. PMID: 32497929. doi:10.1016/j.semarthrit.2020.03.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。